Australian Financial Review
Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other injections with a vaccine patch.
Read More
Chief executive and finance boss out amid job losses, capital raising at start-up Vaxxas
Tess Bennett
16:19
Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other injections with a vaccine patch.
